Extented Platelet Rich Fibrin BlockNCT07424573
Autogenous Bone Block Versus Extended Platelet Rich Fibrin Block for Horizontal Augmentation of Maxillary Ridge With Simultaneous Implant Placement
A study testing group I: autogenous bone block and extented platelet rich fibrin in people with Extented Platelet Rich Fibrin Block, run by Naira elnagar at 1 site in Egypt.
Trial summary
The aim of the study is directed to assess the clinical and radiographic outcomes of autogenous bone block versus extended PRF block used for horizontal augmentation of atrophied esthetic area of maxillary ridge associated with simultaneous implant placement. Read more about this study
- Who is it for?
- Ages 18 to 45 years
- Conditions the study is for
- Extented Platelet Rich Fibrin Block
- What is being tested?
- group I: autogenous bone block and extented platelet rich fibrin
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteEgypt
- Study dates
- 9 May 2024to Apr 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Maxillary narrow ridge in the esthetic anterior zone (about 4-5 mm in width).
- Bone height allows the insertion of at least 8 mm of implant length without the need for vertical augmentation.
- Patient aged 18-45 years old.
- The presence of enough amount of keratinized gingiva as well as enough space for prosthesis rehabilitation.
- Favorable occlusion without presence of parafunctional habits.
- Cooperative patient with high motivation and acceptable oral hygiene.
- Patients are medically free from systemic diseases or drugs that absolutely contraindicate implant surgery.
- Patients able to comply with the required recall visits.
Who cannot join
- Local and / or systemic conditions that may affect passively the clinical procedure or results.
- Heavy smokers(>20 cigarettes/d).(1)
- Alcohol or drug abuse.
- Patients with parafunctional habits (bruxism and clenching).
- Pregnancy.
- Uncooperative patients.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Autogenous Bone Block Versus Extended Platelet Rich Fibrin Block Used for Horizontal Augmentation of Atrophic Esthetic Zone of Maxillary Ridge Associated With Simultaneous Implant Placement
The aim of the study is directed to assess the clinical and radiographic outcomes of autogenous bone block versus extended PRF block used for horizontal augmentation of atrophied esthetic area of maxillary ridge associated with simultaneous implant placement.
Read the detailed description
Twenty implants inserted in 16 patients will be randomly and uniformly distributed into two equal groups:
Group I: Ten dental implants will be inserted simultaneously in eight patients with horizontal ridge augmentation done by symphyseal onlay autogenous block technique.
Group II: Ten dental implants will be inserted simultaneously in nine patients with horizontal ridge augmentation done by onlay extended platelet rich fibrin technique using a mixture of allografts and xenografts.
- Conditions
- Extented Platelet Rich Fibrin Block
- Being tested
- group I: autogenous bone block, extented platelet rich fibrin
- Keywords
- extented platelet rich fibrin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
group I: autogenous bone blockProcedure or surgery
Full thichness flap is done and the implant is inserted in place. After that, an autogenous block is harvested from the symphyseal area and fixed in the area of the defect
extented platelet rich fibrinProcedure or surgery
Full thickness flap is made and the implant is inserted in place. After that the platelet rich fibrin is collected from the patient blood and heated to produce e-platelet rich fibrin, mixed with a mixture of allograft and xenograft to make e-platelet rich fibrin block placed in the defect area
| Study group | Role | What they receive |
|---|---|---|
| Group I ( autogenous bone block) | Experimental | Ten dental implants will be inserted simultaneously with horizontal ridge augmentation done by onlay autogenous block technique. Receives: Procedure: group I: autogenous bone block |
| Group II ( e-prf block) | Experimental | Ten implants were inserted in 9 patients with horizontal augmentation with eprf block. Receives: Procedure: extented platelet rich fibrin |
What is being measured
The primary outcome is the main question the study is designed to answer.
bone width
The horizontal bone gain resulted from the ridge augmentation was measured at 2,4,6 mm apical to the alveolar crest level, then the mean was calculated. This calculation was done at T0 (BG0), T3 (BG3) and T6 (BG6).
Measured: immediately after augmentation and implant placement (T0), and after 3 months (at time of implant loading) (T3) and after six months from implant loading (T6) (totally, 9 months follow up)
Secondary outcomes (9)
bone area
The horizontal bone gain area resulted from the ridge augmentation was measured at T0 (BG0), T3 (BG3) and T6 (BG6).
Measured: immediately after augmentation and implant placement (T0), and after 3 months (at time of implant loading) (T3) and after six months from implant loading (T6) (totally, 9 months follow up)
marginal bone loss
On the cross-sectional view, a line was drawn buccally and lingually just parallel to the long axis of the implant, starting at the most cervical bone implant contact to the apex of the implant. Bone height in millimeters was recorded at immediate postsurgical phase after implant insertion. Vertical bone loss was calculated by subtracting recorded marginal bone level value buccally and lingullay after 3 months (at time of implant loading (T3) and after 6 months of implant loading (T6) from immediate postoperative value (T0).
Measured: immediately after augmentation and implant placement (T0), and after 3 months (at time of implant loading) (T3) and after six months from implant loading (T6) (totally, 9 months follow up)
Relative Alveolar Bone Density
All density records were collected from the cross-sectional view of CBCT using the Hounsfield unit (HU) according to Misch's classification. ROI tool was used representing the average estimated bone density at 3 mid-buccal levels of the placed implant at T0 (immediately after surgery) and after 3 months (at time of implant loading (T3) and after 6 months of implant loading (T6), in comparison to the primary measures.
Measured: immediately after augmentation and implant placement (T0), and after 3 months (at time of implant loading) (T3) and after six months from implant loading (T6) (totally, 9 months follow up)
Bone volume
The volume of the gained bone resulted from the ridge augmentation was measured at T0 (BG0), T3 (BG3) and T6 (BG6).
Measured: immediately after augmentation and implant placement (T0), and after 3 months (at time of implant loading) (T3) and after six months from implant loading (T6) (totally, 9 months follow up)
Postoperative Pain
- By using a 10-point Visual Analogue Scale (VAS) for assessment of pain by the patient on the 1st, 3rd, and 7th days after augmentation surgery. (0-1=None, 2-4=Mild, 5-7=Moderate, 8-10=Severe)
Measured: on the 1st, 3rd, and 7th days after augmentation surgery
Landry Healing Index for Wound Healing Evaluation
- The area of operation was examined by using healing index by Landry et al., this index scores clinical signs and symptoms of infection as redness, hotness, pus discharge, bleeding and pain. In addition to that, any manifestations of wound healing disturbance including wound dehiscence and exposure of underlying bone graft were recorded carefully.
Measured: immediately at 14th day during suture removal visit, one month and 3 months after surgery.
Modified sulcus bleeding Index (mSBI)
Clinical signs and symptoms of inflammation of peri-implant mucosa were graded using criteria of mSBI. It was recorded immediately after implant loading and after 6 months of loading at four aspects around the implants; buccal, lingual, mesial, and distal. The four readings were averaged and approximated to nearest 0.5.
Measured: It was recorded immediately after implant loading and after 6 months of loading.
Peri-implant pocket depth (PPD)
Depth of the peri-implant sulcus was recorded immediately after implant loading and after 6 months of loading. The distance between the gingival margin and the base of the pocket was recorded using a graduated periodontal probe with light force to avoid undue tissue damage and over-extension into the healthy tissue. The probe was inserted buccally, mesially, lingually and distally around each implant in a line parallel to the implant vertical axis until the blunt end of the probe reached the base of the pocket. The four readings were averaged and approximated to nearest 0.5mm.
Measured: immediately after implant loading and after 6 months of loading
Measurement of implant stability
The primary Implant Stability Quotient (ISQ) was measured by using a resonance frequency analyzer (Osstell device) immediately after the placement (T0) and after three months at time of implant loading (T3), then after six months from implant loading (T6). RFA technology depends on fork tuning principle. A Smart Peg was attached to the implant and torqued to 10 Ncm and then the peg was made to vibrate just like a tuning fork by the Osstell device. The purpose here was to find the resonance frequency with the strongest vibration.
Measured: immediately after the placement (T0) and after three months at time of implant loading (T3), then after six months from implant loading (T6).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2026
- Study start9 May 2024
- Primary completion23 Jun 2025
- Study completionApr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Extented Platelet Rich Fibrin BlockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Patients will be randomly and uniformly distributed into two equal groups: Group I: Ten dental implants will be inserted simultaneously with horizontal ridge augmentation done by onlay autogenous block technique. Group II: Ten dental implants will be inserted simultaneously with horizontal ridge augmentation done by onlay extended PRF technique using allograft.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Naira elnagar
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Naira elnagar, Mansoura University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07424573
- Sponsor's protocol ID
- A0203024OS
- Status last verified
- Feb 2026
- First submitted
- 14 Feb 2026
- Last updated
- 24 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: because the data are secret and only the primary researchers have the right to look at them
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Autogenous Bone Block Versus Extended Platelet Rich Fibrin Block Used for Horizontal Augmentation of Atrophic Esthetic Zone of Maxillary Ridge Associated With Simultaneous Implant Placement
- ClinicalTrials.gov ID
- NCT07424573
- Acronym / sponsor ID
- A0203024OS
- Conditions
- Extented Platelet Rich Fibrin Block
- Keywords
- extented platelet rich fibrin
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Naira elnagarUniversity, hospital or other
- Study start
- 9 May 2024 (actual)
- Primary completion
- 23 Jun 2025 (actual)
- Study completion
- Apr 2026 (estimated)
- First posted
- 20 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is directed to assess the clinical and radiographic outcomes of autogenous bone block versus extended PRF block used for horizontal augmentation of atrophied esthetic area of maxillary ridge associated with simultaneous implant placement.
Detailed description
Twenty implants inserted in 16 patients will be randomly and uniformly distributed into two equal groups:
Group I: Ten dental implants will be inserted simultaneously in eight patients with horizontal ridge augmentation done by symphyseal onlay autogenous block technique.
Group II: Ten dental implants will be inserted simultaneously in nine patients with horizontal ridge augmentation done by onlay extended platelet rich fibrin technique using a mixture of allografts and xenografts.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Patients will be randomly and uniformly distributed into two equal groups: Group I: Ten dental implants will be inserted simultaneously with horizontal ridge augmentation done by onlay autogenous block technique. Group II: Ten dental implants will be inserted simultaneously with horizontal ridge augmentation done by onlay extended PRF technique using allograft.
| Arm | Type | Receives |
|---|---|---|
| Group I ( autogenous bone block) | Experimental | Procedure: group I: autogenous bone blockTen dental implants will be inserted simultaneously with horizontal ridge augmentation done by onlay autogenous block technique. |
| Group II ( e-prf block) | Experimental | Procedure: extented platelet rich fibrinTen implants were inserted in 9 patients with horizontal augmentation with eprf block. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Maxillary narrow ridge in the esthetic anterior zone (about 4-5 mm in width).
- Bone height allows the insertion of at least 8 mm of implant length without the need for vertical augmentation.
- Patient aged 18-45 years old.
- The presence of enough amount of keratinized gingiva as well as enough space for prosthesis rehabilitation.
- Favorable occlusion without presence of parafunctional habits.
Key exclusion criteria (6 listed)
- Local and / or systemic conditions that may affect passively the clinical procedure or results.
- Heavy smokers(>20 cigarettes/d).(1)
- Alcohol or drug abuse.
- Patients with parafunctional habits (bruxism and clenching).
- Pregnancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| group I: autogenous bone blockFull thichness flap is done and the implant is inserted in place. After that, an autogenous block is harvested from the symphyseal area and fixed in the area of the defect | Procedure or surgery | Group I ( autogenous bone block) |
| extented platelet rich fibrinFull thickness flap is made and the implant is inserted in place. After that the platelet rich fibrin is collected from the patient blood and heated to produce e-platelet rich fibrin, mixed with a mixture of allograft and xenograft to make e-platelet rich fibrin block placed in the defect area | Procedure or surgery | Group II ( e-prf block) |
Primary outcome
bone width
Time frame: immediately after augmentation and implant placement (T0), and after 3 months (at time of implant loading) (T3) and after six months from implant loading (T6) (totally, 9 months follow up)
The horizontal bone gain resulted from the ridge augmentation was measured at 2,4,6 mm apical to the alveolar crest level, then the mean was calculated. This calculation was done at T0 (BG0), T3 (BG3) and T6 (BG6).
9 secondary outcomes
bone area
Time frame: immediately after augmentation and implant placement (T0), and after 3 months (at time of implant loading) (T3) and after six months from implant loading (T6) (totally, 9 months follow up)
marginal bone loss
Time frame: immediately after augmentation and implant placement (T0), and after 3 months (at time of implant loading) (T3) and after six months from implant loading (T6) (totally, 9 months follow up)
Relative Alveolar Bone Density
Time frame: immediately after augmentation and implant placement (T0), and after 3 months (at time of implant loading) (T3) and after six months from implant loading (T6) (totally, 9 months follow up)
Bone volume
Time frame: immediately after augmentation and implant placement (T0), and after 3 months (at time of implant loading) (T3) and after six months from implant loading (T6) (totally, 9 months follow up)
Postoperative Pain
Time frame: on the 1st, 3rd, and 7th days after augmentation surgery
Landry Healing Index for Wound Healing Evaluation
Time frame: immediately at 14th day during suture removal visit, one month and 3 months after surgery.
Modified sulcus bleeding Index (mSBI)
Time frame: It was recorded immediately after implant loading and after 6 months of loading.
Peri-implant pocket depth (PPD)
Time frame: immediately after implant loading and after 6 months of loading
Measurement of implant stability
Time frame: immediately after the placement (T0) and after three months at time of implant loading (T3), then after six months from implant loading (T6).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2026.
- Individual participant dataSharing planned: No. because the data are secret and only the primary researchers have the right to look at them
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing group I: autogenous bone block and extented platelet rich fibrin in people with Extented Platelet Rich Fibrin Block, run by Naira elnagar at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 24 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
bone width (time frame: immediately after augmentation and implant placement (T0), and after 3 months (at time of implant loading) (T3) and after six months from implant loading (T6) (totally, 9 months follow up)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2026; AzTrials last refreshed its copy on 6 Nov 2026.